PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Liu, Shi He ^a,b   Rao, Donald D ^c   Nemunaitis, John ^c,d,e   Senzer, Neil ^c,d,e   Zhou, Guisheng ^a,b   Dawson, David ^a   Gingras, Marie Claude ^b   Wang, Zhaohui ^c   Gibbs, Richard ^b   Norman, Michael ^b   Templeton, Nancy S ^c   DeMayo, Francesco J ^b   O'Malley, Bert ^b   Sanchez, Robbi ^a   Fisher, William E ^b   Brunicardi, F Charles ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c GRADALIS INC   (United States)

^d Mary Crowley Cancer Research Centers   (United States)

^e TEXAS ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPLEX; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PDX 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPOGLYCEMIA; IMMUNOCHEMISTRY; IMMUNOCOMPETENCE; INSULINOMA; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET; PANCREAS TUMOR; PROTEIN EXPRESSION; RNA INTERFERENCE; SYMPTOM; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INSULIN; INSULINOMA; ISLETS OF LANGERHANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PANCREAS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TRANS-ACTIVATORS;

EID: 84864667426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040452     Document Type: Article

References (41)

1. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, et al. (1996) PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122: 983-995.
2. Hui H, Perfetti R, (2002) Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur J Endocrinol 146: 129-141.
3. McKinnon CM, Docherty K, (2001) Pancreatic duodenal homeobox-1, PDX-1, a major regulator of beta cell identity and function. Diabetologia 44: 1203-1214.
4. Gannon M, Ables ET, Crawford L, Lowe D, Offield MF, et al. (2008) pdx-1 function is specifically required in embryonic beta cells to generate appropriate numbers of endocrine cell types and maintain glucose homeostasis. Dev Biol 314: 406-417.
5. Stoffers D, Ferrer J, Clarke W, Habener J, (1997) Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nature Genet 17: 138-139.
6. Shih DQ, Stoffel M, (2002) Molecular etiologies of MODY and other early-onset forms of diabetes. Curr Diab Rep 2: 125-134.
7. Miyatsuka T, Kaneto H, Shiraiwa T, Matsuoka TA, Yamamoto K, et al. (2006) Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev 20: 1435-1440.
8. Li Y, Zhang R, Qiao H, Zhang H, Wang Y, et al. (2007) Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells. J Cell Physiol 211: 36-44.
9. Koizumi M, Doi R, Fujimoto K, Ito D, Toyoda E, et al. (2005) Pancreatic epithelial cells can be converted into insulin-producing cells by GLP-1 in conjunction with virus-mediated gene transfer of pdx-1. Surgery 138: 125-133.
10. Wang X, Zhou J, Doyle ME, Egan JM, (2001) Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142: 1820-1827.
11. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, et al. (2009) Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 284: 33509-33520.
12. Zhou J, Pineyro MA, Wang X, Doyle ME, Egan JM, (2002) Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. J Cell Physiol 192: 304-314.
13. Zalzman M, Anker-Kitai L, Efrat S, (2005) Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes 54: 2568-2575.
14. Watada H, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, et al. (1996) PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of betacellulin. Diabetes 45: 1826-1831.
15. Carty MD, Lillquist JS, Peshavaria M, Stein R, Soeller WC, (1997) Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. J Biol Chem 272: 11986-11993.
16. Watada H, Kajimoto Y, Kaneto H, Matsuoka T, Fujitani Y, et al. (1996) Involvement of the homeodomain-containing transcription factor PDX-1 in islet amyloid polypeptide gene transcription. Biochem Biophys Res Commun 229: 746-751.
17. Serup P, Jensen J, Andersen FG, Jorgensen MC, Blume N, et al. (1996) Induction of insulin and islet amyloid polypeptide production in pancreatic islet glucagonoma cells by insulin promoter factor 1. Proc Natl Acad Sci U S A 93: 9015-9020.
18. Bischof LJ, Martin CC, Svitek CA, Stadelmaier BT, Hornbuckle LA, et al. (2001) Characterization of the mouse islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter by in situ footprinting: correlation with fusion gene expression in the islet-derived betaTC-3 and hamster insulinoma tumor cell lines. Diabetes 50: 502-514.
19. Waeber G, Thompson N, Nicod P, Bonny C, (1996) Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. Mol Endocrinol 10: 1327-1334.
20. Jepeal LI, Fujitani Y, Boylan MO, Wilson CN, Wright CV, et al. (2005) Cell-specific expression of glucose-dependent-insulinotropic polypeptide is regulated by the transcription factor PDX-1. Endocrinology 146: 383-391.
21. Elbein S, Chu W, Ren Q, Hemphill C, Schay J, et al. (2002) Role of calpain-10 gene variants in familial type 2 diabetes in Caucasians. J Clin Endocrinol Metab 87: 650-654.
22. Ashizawa S, Brunicardi FC, Wang XP, (2004) PDX-1 and the pancreas. Pancreas 28: 109-120.
23. Liu S, Ballian N, Belaguli NS, Patel S, Li M, et al. (2008) PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas 37: 210-220.
24. Liu SH, Patel S, Gingras MC, Nemunaitis J, Zhou G, et al. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer 117: 723-733.
25. Koizumi M, Doi R, Toyoda E, Masui T, Tulachan SS, et al. (2003) Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 134: 260-266.
26. Liu T, Gou SM, Wang CY, Wu HS, Xiong JX, et al. (2007) Pancreas duodenal homeobox-1 expression and significance in pancreatic cancer. World J Gastroenterol 13: 2615-2618.
27. Wang XP, Li ZJ, Magnusson J, Brunicardi FC, (2005) Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers. World J Surg 29: 334-338.
28. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, et al. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther 17: 780-791.
29. Liu S, Wang XP, Brunicardi FC, (2007) Enhanced cytotoxicity of RIPTK gene therapy of pancreatic cancer via PDX-1 co-delivery. J Surg Res 137: 1-9.
30. Rao DD, Senzer N, Cleary MA, Nemunaitis J, (2009) Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 16: 807-809.
31. Rao DD, Vorhies JS, Senzer N, Nemunaitis J, (2009) siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61: 746-759.
32. Templeton NS, (2002) Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22: 283-295.
33. Simberg D, Weiss A, Barenholz Y, (2005) Reversible mode of binding of serum proteins to DOTAP/cholesterol Lipoplexes: a possible explanation for intravenous lipofection efficiency. Hum Gene Ther 16: 1087-1096.
34. Ramesh RST, Templeton NS, Ji L, Stephens LC, Ito I, et al. (2001) Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3: 337-350.
35. Ito IJL, Tanaka F, Saito Y, Gopalan B, Branch CD, et al. (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11: 733-739.
36. Nemunaitis G, Maples PB, Jay C, Gahl WA, Huizing M, et al. (2010) Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J Gene Med 12: 403-412.
37. Lu C, Stewart DJ, Ji L, Ramesh R, O'Connor S, et al. (2010) Systemic Gene Therapy with Tumor Suppressor FUS1-nanoparticles for Recurrent/Metastatic Lung Cancer. J Clin Oncol 28: 15s (suppl.; abstract 7582).
38. Kaltsas GA, Besser GM, Grossman AB, (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25: 458-511.
39. Feanny MA, Fagan SP, Ballian N, Liu SH, Li Z, et al. (2008) PDX-1 expression is associated with islet proliferation in vitro and in vivo. J Surg Res 144: 8-16.
40. Liu T, Wang C, Wan C, Xiong J, Xu Y, et al. (2004) PDX-1 expression in pancreatic ductal cells after partial pancreatectomy in adult rats. J Huazhong Univ Sci Technolog Med Sci 24: 464-466.
41. Taguchi M, Yamaguchi T, Otsuki M, (2002) Induction of PDX-1-positive cells in the main duct during regeneration after acute necrotizing pancreatitis in rats. J Pathol 197: 638-646.